For Clay Siegall, Cancer Needs To Die
Clay Siegall is a scientist by trade and a successful entrepreneur by chance. After graduating from the University of Maryland with a Bachelor’s degree in Zoology, Clay went to medical school at George Washington University. He received his PhD from GWU with an emphasis in Genetics. Clay has made it his life’s work to find a cure for cancer and since 2008 he has been the President, Chairman, and CEO of Seattle Gentetics.
Clay started Seattle Genetics, a Seattle-based biotechnology company, way back in 1998. The company’s goal is to develop and create monoclonal antibody conjugates that deliver cancer-killing agents to the cancer cells themselves. They are the premier biotechnology company in the world that specializes in these antibody conjugates. The company has over 900 employees as of 2016 and was recently acquired by Cascadian Therapeutics. In 2001, the company went publicly and currently trades on the NASDAQ stock exchange under the SGEN symbol.
Clay Siegall is active member of the pharmaceutical directors community, serving on the board of several pharma companies. Siegall serves on the board of directors of Alder Biopharmaceuticals, Mirna Therapeutics, and Ultragenyx Pharmaceuticals. He is an active member in the Seattle community and has won a number of awards for his work at Seattle Genetics. In 2012, Siegall was named the Alumnus of the Year in Math and Sciences by his alma mater, the University of Maryland. The following year he was awarded the Entrepreneur of the Year for the Pacific Northwest by ratings agency Ernst & Young.